Total Funding
31
11
Total FundingSeries A raised
Growth Score 31 in past quarter
-3 pts
Heat Score 11 in past quarter
-34 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
167999
Capio Biosciences focuses on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes.
Andrew Wang: Co-Founder
Seungpyo Hong: Co-founder and President
About the Company
Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell
rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.
